Study Reveals Challenges in Musculoskeletal Classification of Psoriasis, PsA
While the results showed a high prevalence of suspected musculoskeletal symptoms in patients with psoriasis, only a small number were due to psoriatic arthritis.
Stay updated with breaking news from Bone Spine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
While the results showed a high prevalence of suspected musculoskeletal symptoms in patients with psoriasis, only a small number were due to psoriatic arthritis.
The incidences of stroke, ischemic heart disease, or heart failure were slightly higher in patients with gout when compared with controls.
Usual interstitial pneumonia (UIP) is characterised by a distinctive morphological and radiological appearance that was considered the pathognomonic hallmark of idiopathic pulmonary fibrosis (IPF). However, this peculiar lung remodelling pattern is also seen in other fibrotic interstitial lung diseases, including hypersensitivity pneumonitis, and connective tissue diseases. In this Personal View, we advocate the designation of a UIP pattern as a single, discrete diagnostic entity, amalgamating its primary form and secondary processes in disorders such as hypersensitivity pneumonitis (hypersens...
Systemic sclerosis, also known as scleroderma, is a rare and complex autoimmune connective-tissue disease. Once considered an untreatable and unpredictable condition, research advancements have improved our understanding of its disease pathogenesis and clinical phenotypes and expanded our treatment armamentarium. Early and accurate diagnosis is essential, while ongoing efforts to risk stratify patients have a central role in predicting both organ involvement and disease progression. A holistic approach is required when choosing the optimal therapeutic strategy, balancing the side-effect profil...
Pfizer Inc. announced today that the European Commission has approved XELJANZ ® for the treatment of active polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis in patients two years of age and older who have responded inadequately to previous therapy with disease modifying antirheumatic drugs . Two formulations were approved, a tablet and a new oral solution . XELJANZ is the first and only ...